Comparison of the effects of tibolone and estrogen therapy on hemostasis in surgical menopause: a randomized, double-blind, placebo-controlled study

Fertility and Sterility

Volumn 87, Issue 4, 2007, Pages 842-848

  Demirol, Aygul ^a   Guven, Suleyman ^b   Guvendag Guven, Emine Seda ^c   Kirazli, Serafettin ^d   Gurgan, Timur ^d   Ayhan, Ali ^d  

^a Department of IVF   (Turkey)

^b KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^c Etlik Maternity and Women's Health Teaching Hospital   (Turkey)

^d HACETTEPE UNIVERSITY   (Turkey)

Author keywords

coagulation; estradiol; fibrinolysis; hemostasis; surgical menopause; Tibolone

Indexed keywords

BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9; CONJUGATED ESTROGEN; FIBRINOGEN; LIPOPROTEIN A; PLACEBO; TIBOLONE;

ADULT; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; PARTIAL THROMBOPLASTIN TIME; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ANTITHROMBIN III; BLOOD COAGULATION FACTORS; DOUBLE-BLIND METHOD; ESTROGENS, CONJUGATED (USP); FEMALE; HEMOSTASIS; HUMANS; HYSTERECTOMY; LIPOPROTEIN(A); MENOPAUSE; MIDDLE AGED; NORPREGNENES; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDIES; SALPINGOSTOMY; VENOUS THROMBOSIS;

EID: 34047258151     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2006.08.090     Document Type: Article

References (46)

1. Mosca L., Manson J.E., Sutherland S.E., Langer R.D., Manolio T., Barrett-Connor E., and Writing Group. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Circulation 96 (1997) 2468-2482
2. Lerner D.J., and Kannel W.B. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 111 (1986) 383-390
3. Lip G.Y., Blann A.D., Jones A.F., and Beevers D.G. Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. Am Heart J 134 (1997) 764-771
4. Nordstrom M., Lindblad B., Bergqvist D., and Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 232 (1992) 155-160
5. Petitti D.B., Wingerd J., Pellegrin F., and Ramcharan S. Risk of vascular disease in women. Smoking, oral contraceptives, noncontraceptive estrogens, and other factors. JAMA 242 (1979) 1150-1154
6. Devor M., Barrett-Connor E., Renvall M., Feigal Jr. D., and Ramsdell J. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 92 (1992) 275-282
7. Nachtigall L.E., Nachtigall R.H., Nachtigall R.D., and Beckman E.M. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 54 (1979) 74-79
8. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. A report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. N Engl J Med 290 (1974) 15-19
9. Daly E., Vessey M.P., Hawkins M.M., Carson J.L., Gough P., and Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348 (1996) 977-980
10. Grodstein F., Stampfer M.J., Goldhaber S.Z., Manson J.E., Colditz G.A., Speizer F.E., et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 348 (1996) 983-987
11. Jick H., Derby L.E., Myers M.W., Vasilakis C., and Newton K.M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348 (1996) 981-983
12. Perez Gutthann S., Garcia Rodriguez L.A., Castellsague J., and Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 314 (1997) 796-800
13. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E., and Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998) 605-613
14. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
15. Hsia J., Langer R.D., Manson J.E., Kuller L., Johnson K.C., Hendrix S.L., et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 166 (2006) 357-365
16. Bjarnason N.H., Bjarnason K., Haarbo J., Bennink H.J., and Christiansen C. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab 82 (1997) 1752-1756
17. Winkler U.H., Altkemper R., Kwee B., Helmond F.A., and Coelingh Bennink H.J. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. Fertil Steril 74 (2000) 10-19
18. van Wersch J.W., Ubachs J.M., van den Ende A., and van Enk A. The effect of two regimens of hormone replacement therapy on the haemostatic profile in postmenopausal women. Eur J Clin Chem Clin Biochem 32 (1994) 449-453
19. Lensing A.W., Prandoni P., Prins M.H., and Buller H.R. Deep-vein thrombosis. Lancet 353 (1999) 479-485
20. Colditz G.A., Willett W.C., Stampfer M.J., Rosner B., Speizer F.E., and Hennekens C.H. Menopause and the risk of coronary heart disease in women. N Engl J Med 316 (1987) 1105-1110
21. Boschetti C., Cortellaro M., Nencioni T., Bertolli V., Della Volpe A., and Zanussi C. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women. Thromb Res 62 (1991) 1-8
22. Kroon U.B., Silfverstolpe G., and Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost 71 (1994) 420-423
23. Caine Y.G., Bauer K.A., Barzegar S., ten Cate H., Sacks F.M., Walsh B.W., et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 68 (1992) 392-395
24. Koh K.K., Han S.H., Shin M.S., Ahn J.Y., Lee Y., and Shin E.K. Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study. Eur Heart J 26 (2005) 1362-1368
25. Ball M.J., Ashwell E., and Gillmer M.D. Progestagen-only oral contraceptives: comparison of the metabolic effects of levonorgestrel and norethisterone. Contraception 44 (1991) 223-233
26. Kuhl H. Effects of progestogens on haemostasis. Maturitas 24 (1996) 1-19
27. Winkler U.H. Effects of androgens on haemostasis. Maturitas 24 (1996) 147-155
28. Jaillard A.S., Hommel M., and Mallaret M. Venous sinus thrombosis associated with androgens in a healthy young man. Stroke 25 (1994) 212-213
29. Mammen E. Androgens and antiandrogens. Gynecol Endocrinol 7 Suppl (1993) 79-86
30. Rosati D., Micheli S., Pinto S., Fedi S., Bruni V., Bucciantini S., et al. Changes in lipidic and hemostatic parameters induced by tibolone treatment. Thromb Res 85 (1997) 273-278
31. Peverill R.E. Hormone therapy and venous thromboembolism. Best Pract Res Clin Endocrinol Metab 17 (2003) 149-164
32. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 273 (1995) 199-208
33. Kroon U.B., Tengborn L., Rita H., and Backstrom A.C. The effects of transdermal oestradiol and oral progestogens on haemostasis variables. Br J Obstet Gynaecol 104 Suppl 16 (1997) 32-37
34. Andersen L.F., Gram J., Skouby S.O., and Jespersen J. Effects of hormone replacement therapy on hemostatic cardiovascular risk factors. Am J Obstet Gynecol 180 (1999) 283-289
35. Frohlich M., Schunkert H., Hense H.W., Tropitzsch A., Hendricks P., Doring A., et al. Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women. Br J Haematol 100 (1998) 577-581
36. Conard J., Gompel A., Pelissier C., Mirabel C., and Basdevant A. Fibrinogen and plasminogen modifications during oral estradiol replacement therapy. Fertil Steril 68 (1997) 449-453
37. Chen F.P., Lee N., Wang C.H., Cherng W.J., and Soong Y.K. Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women. Fertil Steril 69 (1998) 267-273
38. Demirol A., Baykal C., Kirazli S., and Ayhan A. Effects of hormone replacement on hemostasis in spontaneous menopause. Menopause 8 (2001) 135-140
39. Kessler C.M., Szymanski L.M., Shamsipour Z., Muesing R.A., Miller V.T., and LaRosa J.C. Estrogen replacement therapy and coagulation: relationship to lipid and lipoprotein changes. Obstet Gynecol 89 (1997) 326-331
40. Koh K.K., Ahn J.Y., Jin D.K., Yoon B.K., Kim H.S., Kim D.S., et al. Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-controlled, crossover study. Arterioscler Thromb Vasc Biol 23 (2003) 1889-1894
41. Haines C., Chung T., Chang A., Masarei J., Tomlinson B., Wong E., A randomized, double-blind, placebo-controlled, and crossover study. Effect of oral estradiol on Lp(a) and other lipoproteins in postmenopausal women. Arch Intern Med 156 (1996) 866-872
42. Bolibar I., Thompson S.G., von Eckardstein A., Sandkamp M., Assmann G., and ECAT Angina Pectoris Study Group. Dose-response relationships of serum lipid measurements with the extent of coronary stenosis. Strong, independent, and comprehensive. Arterioscler Thromb Vasc Biol 15 (1995) 1035-1042
43. Loscalzo J., Weinfeld M., Fless G.M., and Scanu A.M. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 10 (1990) 240-245
44. Su W., Campos H., Judge H., Walsh B.W., and Sacks F.M. Metabolism of Apo(a) and ApoB100 of lipoprotein(a) in women: effect of postmenopausal estrogen replacement. J Clin Endocrinol Metab 83 (1998) 3267-3276
45. Olivieri O., Friso S., Manzato F., Guella A., Bernardi F., Lunghi B., et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 91 (1995) 465-470
46. Price D.T., and Ridker P.M. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med 127 (1997) 895-903